Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elicio Therapeutics, Inc.ANGN · Entity 299 | Director | July 01, 2022 | July 11, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elicio Therapeutics, Inc.
Report date July 01, 2022 · Filed July 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,687,986 |
Reported balance
After 2022-07-01 transaction · row 1
1 source rowRow 1 · 2022-07-01 · Tax withholding · Disposed 32,082 · Balance 1,687,986 F1: The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2022 Filed Jul 11, 2022 19:54 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | Tax withholdingCommon Stock | 32,082 | $1.12 | $35,931.84 |
DisclosureSEC source: 0001601485-22-000059 · wf-form4_165758365151556.xml · nonDerivative · entry 1 Goldberg Itzhak · CIK 0001607858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,687,986 F1 · kind: The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| December 06, 2021 Filed Dec 7, 2021 16:06 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 32,118 | $3.35 | $107,720.56 |
DisclosureSEC source: 0001601485-21-000081 · wf-form4_163891118480825.xml · nonDerivative · entry 1 Goldberg Itzhak · CIK 0001607858 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,720,068 F1 · kind: The shares reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2021 by the Reporting Person F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.21 to $3.45 inclusive. Read SEC document |
| December 03, 2021 Filed Dec 3, 2021 18:03 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 40,215 | $3.39 | $136,216.25 |
DisclosureSEC source: 0001601485-21-000079 · wf-form4_163857259870004.xml · nonDerivative · entry 3 Goldberg Itzhak · CIK 0001607858 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,752,186 F1 · kind: The shares reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2021 by the Reporting Person F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.29 to $3.50 inclusive. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 18:03 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 38,800 | $3.51 | $136,327.68 |
DisclosureSEC source: 0001601485-21-000079 · wf-form4_163857259870004.xml · nonDerivative · entry 2 Goldberg Itzhak · CIK 0001607858 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,792,401 F1 · kind: The shares reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2021 by the Reporting Person F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.36 to $3.64 inclusive. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 18:03 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 38,867 | $3.54 | $137,666.91 |
DisclosureSEC source: 0001601485-21-000079 · wf-form4_163857259870004.xml · nonDerivative · entry 1 Goldberg Itzhak · CIK 0001607858 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,831,201 F1 · kind: The shares reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2021 by the Reporting Person F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.31 to $3.79 inclusive. Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 18:02 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 38,495 | $4.26 | $163,807.77 |
DisclosureSEC source: 0001601485-21-000075 · wf-form4_163719012500153.xml · nonDerivative · entry 3 Goldberg Itzhak · CIK 0001607858 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,870,068 F2 · kind: The shares reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2021 by the Reporting Person F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.21 to $4.38 inclusive. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 18:02 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | SaleCommon Stock | 111,505 | $4.17 | $465,243.46 |
DisclosureSEC source: 0001601485-21-000075 · wf-form4_163719012500153.xml · nonDerivative · entry 2 Goldberg Itzhak · CIK 0001607858 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,908,563 F2 · kind: The shares reported in this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2021 by the Reporting Person F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.48 inclusive. Read SEC document |
| June 24, 2021 Filed Nov 17, 2021 18:02 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | Tax withholdingCommon Stock | 47,410 | $13.78 | $653,309.80 |
DisclosureSEC source: 0001601485-21-000075 · wf-form4_163719012500153.xml · nonDerivative · entry 1 Goldberg Itzhak · CIK 0001607858 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,020,068 F1 · kind: The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 19:23 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | Tax withholdingCommon Stock | 38,353 | $16.00 | $613,648.00 |
DisclosureSEC source: 0001567619-21-003190 · doc1.xml · nonDerivative · entry 1 Goldberg Itzhak · CIK 0001607858 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,067,478 F1 · kind: The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 239,912 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 12:58 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 70,012 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001567619-21-002412 · doc1.xml · derivative · entry 1 Goldberg Itzhak · CIK 0001607858 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,012 Underlying: Common Stock · 70,012 shares Expires 2031-02-03 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.